8 July 2020
This award recognizes outstanding contributions to the advancement of AD research published in the Journal of Alzheimer's Disease
Amsterdam, NL – The Journal of Alzheimer’s Disease (JAD) is pleased to announce that the joint recipients of the 2020 Alzheimer Award are Christin Nance, BA, and Sarah Banks, PhD.
The 2020 winning paper is Nance C, Ritter A, Miller JB, Lapin B, and Banks SJ (2019) “The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease,” J Alzheimers Dis, 70, 983–993. It is freely available to everyone to read, download, and share.
Each year, JAD’s Associate Editors select the article published during the previous year that has had the most significant impact on Alzheimer’s disease (AD) research. The awardee(s) receives the Alzheimer Medal, a bronze medal with the likeness of Alois Alzheimer, and a cash award of $7,500.
This year’s award-winning article addresses one of the primary challenges in managing AD: the variable rate of cognitive decline among patients. Individuals diagnosed with AD who experience rapid cognitive decline (RCD) are associated with worse functional outcomes and a higher mortality rate than those with normal rates of cognitive decline (NCD). “The fact that there is no current consensus on the baseline risk factors for RCD in AD warranted further exploration,” explained Ms. Nance.
In order to investigate the demographic, clinical and pathological differences between RCD and NCD in AD, data on individuals with clinically-diagnosed AD, taken from the National Alzheimer’s Coordinating Center (NACC) Uniform Data Set, were compared with autopsy data from the NACC Neuropathology Data Set. To the authors' knowledge, this is the largest autopsy sample studied for defining clinical characteristics and variables of cognitive status in RCD.
The central findings of the study suggest that individuals with RCD had a more severe pathological signature than those with NCD: higher prevalence of comorbidities; more severe cerebral amyloid angiopathy; more diffuse neocortical Lewy bodies; and greater gross lobar atrophy. Despite similar baseline Mini-Mental Status Examination scores, individuals with RCD had lower baseline neuropsychology test scores in domains of language and memory (WMS Logical Memory Immediate Recall, Animal Naming, Boston Naming Test) as well as executive functioning (Trails B and WAIS-R Digit Symbol).
In contrast with previous research, none of the demographic factors observed differed significantly between groups in this sample. “The results of our study suggest that further research is necessary to better capture the early profile of patients most likely to experience RCD,” commented Dr. Banks.
2020 Alzheimer Award Recipients:
Christin Nance, BA, earned her undergraduate degree in Psychology in 2015 at the University of Nevada, Las Vegas, where she conducted research on the psychophysiology of emotion and personality. Subsequently, she joined the Cleveland Clinic Lou Ruvo Center for Brain Health as a research coordinator and Certified Specialist in Psychometry (CSP), working with the neuropsychology team. Most notably, she coordinated novel investigations of the GE-180 PET ligand under a Centers of Biomedical Research Excellence (COBRE) grant funded by the National Institutes of Health (NIH) and the National Institute of General Medical Sciences (NIGMS). Her efforts were instrumental in obtaining the GE-180 Investigational New Drug (IND) license under Federal Drug Administration (FDA) approval, facilitating research on the relationship between neuropsychology test scores and biomarkers of inflammation in patients with AD and Parkinson’s disease. In 2019, she joined the technology/health start-up Ready Responders and now provides clinical patient care at a Las Vegas homeless shelter during the SARS CoV-2 pandemic.
Sarah Banks, PhD, is a board-certified neuropsychologist and Associate Professor of Neurosciences and modifiable risk factors in AD. Dr. Banks earned her BSc in Psychology at the University of Edinburgh in her native UK, then her PhD at Northwestern University’s Feinberg School of Medicine (Chicago), before completing her postdoctoral fellowship at the Montreal Neurological Institute, part of McGill University. She then moved back to the US in 2011 to initiate the Cleveland Clinic Lou Ruvo Center of Brain Health’s Neuropsychology Program in Las Vegas, NV. She led this program through its expansion before joining the team at UC San Diego in 2018 where she continues her research combining imaging, cognition and genetics of AD, in addition to directing the neuropsychology program of a new multidisciplinary memory disorders clinic. Her clinical and research focus is AD and related disorders. She has a particular interest in better understanding how cognitive measures and biomarkers correspond to pathology and how factors including sex impact these relationships, as well how we can adjust lifestyle factors to mitigate risk of cognitive decline.
“We would like to gratefully acknowledge our co-investigators and their essential contributions to our research findings, as well as the NACC team who offer such a rich resource for this kind of research. We would also like to thank the members of the JAD Editorial Board for selecting our paper from among the 800+ excellent articles published by the journal in 2019,” stated Ms. Nance and Dr. Banks.
“The Associate Editors and I are delighted to formally recognize Christin Nance and Sarah Banks for this significant work. While the disease profile and definition of RCD are not fully understood, this research, using autopsy confirmation of AD (the ‘gold standard’) to better elucidate both the underlying pathology and clinical characteristics of RCD, significantly advances our understanding,” commented George Perry, PhD, Editor-in-Chief, Journal of Alzheimer's Disease, and Semmes Foundation Distinguished University Chair in Neurobiology at The University of Texas at San Antonio.
NOTES FOR EDITORS
Winning paper (openly available): Nance C, Ritter A, Miller JB, Lapin B, and Banks SJ (2019), ”The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease,” J Alzheimers Dis, 70, 983–993 (DOI 10.3233/JAD-190302). The open access paper is available at: content.iospress.com/articles/journal-of-alzheimers-disease/jad190302.
Click here to view information about previous Alzheimer Award winners.
George Perry, PhD, The University of Texas at San Antonio, USA (+1 210 458 4450 or firstname.lastname@example.org) and Carmel McNamara, PhD, IOS Press, Amsterdam, NL (+31 20 688 3355 or email@example.com).
About the Journal of Alzheimer's Disease
Now in its 223d year of publication, the Journal of Alzheimer's Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a 2019 Journal Impact Factor of 3.909 according to Journal Citation Reports (Clarivate, 2020). It is published by IOS Press. j-alz.com
About IOS Press
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes more than 80 international peer-reviewed journals and about 75 book titles each year on subjects ranging from computer science, artificial intelligence, and engineering to medicine, neuroscience, and cancer research. iospress.com